Belotecan shows promise in both platinum-resistant and -sensitive ovarian cancer

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1648, 2008-01, pp. : 9-9

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment of platinum-resistant ovarian cancer

By Trimble Edward L Wright John Christian Michaele C

Expert Opinion on Pharmacotherapy, Vol. 2, Iss. 8, 2001-08 ,pp. : 1299-1306

Informa Healthcare

Access to resources Recommend Favorite

Management Strategies for Recurrent Platinum-Resistant Ovarian Cancer

By Naumann R. Wendel

Drugs, Vol. 71, Iss. 11, 2011-07 ,pp. : 1397-1412

Adis International

Access to resources Recommend Favorite

Investigational agents against platinum-resistant ovarian cancer

By Lorusso Domenica Ferrandina Gabriella Fanfani Francesco Gagliardi Maria Lucia Scambia Giovanni

Expert Opinion on Investigational Drugs, Vol. 16, Iss. 3, 2007-03 ,pp. : 325-336

Informa Healthcare

Access to resources Recommend Favorite

Optimal therapy for platinum-resistant recurrent ovarian cancer: doxorubicin, gemcitabine or topotecan?

By Pectasides Dimitris Psyrri Amanda Pectasides Melina Economopoulos Theofanis

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 8, 2006-06 ,pp. : 975-987

Informa Healthcare

Access to resources Recommend Favorite

Targeting Platinum Resistant Disease in Ovarian Cancer

Current Medicinal Chemistry, Vol. 21, Iss. 26, 2014-09 ,pp. : 3009-3020

Bentham Science Publishers

Access to resources Recommend Favorite